Brief: Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Plozasiran
02/12/2025 13:18
Dec 2 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O: ARROWHEAD PHARMACEUTICALS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR PLOZASIRAN IN SEVERE HYPERTRIGLYCERIDEMIA ARROWHEAD PHARMACEUTICALS - TO COMPLETE PHASE 3 STUDIES BY MID-2026 ARROWHEAD PHARMACEUTICALS: INTENDS TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO FDA BY YEAR-END 2026 Source text: ID:nBw8DHM9Sa Further company coverage: ARWR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers